nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Topotecan—cervical cancer	0.414	0.634	CbGbCtD
Dabrafenib—ABCB1—Topotecan—cervical cancer	0.149	0.229	CbGbCtD
Dabrafenib—CYP3A4—Topotecan—cervical cancer	0.0894	0.137	CbGbCtD
Dabrafenib—NEK11—uterine cervix—cervical cancer	0.0116	0.0676	CbGeAlD
Dabrafenib—NEK11—uterus—cervical cancer	0.0097	0.0563	CbGeAlD
Dabrafenib—NEK11—female reproductive system—cervical cancer	0.00872	0.0506	CbGeAlD
Dabrafenib—LIMK1—decidua—cervical cancer	0.00793	0.0461	CbGeAlD
Dabrafenib—NEK11—female gonad—cervical cancer	0.00793	0.0461	CbGeAlD
Dabrafenib—LIMK1—vagina—cervical cancer	0.00564	0.0328	CbGeAlD
Dabrafenib—NEK11—lymph node—cervical cancer	0.0051	0.0296	CbGeAlD
Dabrafenib—BRAF—endometrium—cervical cancer	0.00465	0.027	CbGeAlD
Dabrafenib—SIK1—uterine cervix—cervical cancer	0.00431	0.025	CbGeAlD
Dabrafenib—BRAF—uterus—cervical cancer	0.00429	0.0249	CbGeAlD
Dabrafenib—SIK1—decidua—cervical cancer	0.0041	0.0238	CbGeAlD
Dabrafenib—SIK1—renal system—cervical cancer	0.00403	0.0234	CbGeAlD
Dabrafenib—SIK1—endometrium—cervical cancer	0.00389	0.0226	CbGeAlD
Dabrafenib—SIK1—mammalian vulva—cervical cancer	0.00377	0.0219	CbGeAlD
Dabrafenib—LIMK1—lymph node—cervical cancer	0.00365	0.0212	CbGeAlD
Dabrafenib—SIK1—uterus—cervical cancer	0.00359	0.0208	CbGeAlD
Dabrafenib—BRAF—female gonad—cervical cancer	0.00351	0.0204	CbGeAlD
Dabrafenib—BRAF—vagina—cervical cancer	0.00349	0.0202	CbGeAlD
Dabrafenib—RAF1—epithelium—cervical cancer	0.00346	0.0201	CbGeAlD
Dabrafenib—RAF1—uterine cervix—cervical cancer	0.00343	0.0199	CbGeAlD
Dabrafenib—Rash erythematous—Topotecan—cervical cancer	0.00328	0.0553	CcSEcCtD
Dabrafenib—RAF1—decidua—cervical cancer	0.00327	0.019	CbGeAlD
Dabrafenib—SIK1—female reproductive system—cervical cancer	0.00323	0.0187	CbGeAlD
Dabrafenib—RAF1—renal system—cervical cancer	0.00321	0.0186	CbGeAlD
Dabrafenib—RAF1—endometrium—cervical cancer	0.0031	0.018	CbGeAlD
Dabrafenib—Rigors—Topotecan—cervical cancer	0.00308	0.0518	CcSEcCtD
Dabrafenib—SLCO1B3—vagina—cervical cancer	0.003	0.0174	CbGeAlD
Dabrafenib—RAF1—mammalian vulva—cervical cancer	0.003	0.0174	CbGeAlD
Dabrafenib—SIK1—female gonad—cervical cancer	0.00294	0.017	CbGeAlD
Dabrafenib—RAF1—uterus—cervical cancer	0.00286	0.0166	CbGeAlD
Dabrafenib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00277	0.0465	CcSEcCtD
Dabrafenib—RAF1—female reproductive system—cervical cancer	0.00257	0.0149	CbGeAlD
Dabrafenib—SLCO1B1—renal system—cervical cancer	0.0024	0.0139	CbGeAlD
Dabrafenib—RAF1—female gonad—cervical cancer	0.00234	0.0136	CbGeAlD
Dabrafenib—RAF1—vagina—cervical cancer	0.00232	0.0135	CbGeAlD
Dabrafenib—Rash maculo-papular—Topotecan—cervical cancer	0.00229	0.0385	CcSEcCtD
Dabrafenib—Neoplasm—Topotecan—cervical cancer	0.00227	0.0383	CcSEcCtD
Dabrafenib—BRAF—lymph node—cervical cancer	0.00225	0.0131	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—cervical cancer	0.00192	0.0112	CbGeAlD
Dabrafenib—Dermatitis bullous—Topotecan—cervical cancer	0.00191	0.0321	CcSEcCtD
Dabrafenib—SIK1—lymph node—cervical cancer	0.00189	0.011	CbGeAlD
Dabrafenib—SLC22A8—renal system—cervical cancer	0.00186	0.0108	CbGeAlD
Dabrafenib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00164	0.0277	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00161	0.0271	CcSEcCtD
Dabrafenib—RAF1—lymph node—cervical cancer	0.0015	0.00872	CbGeAlD
Dabrafenib—Neutropenia—Topotecan—cervical cancer	0.00148	0.0248	CcSEcCtD
Dabrafenib—ABCG2—uterine cervix—cervical cancer	0.00142	0.00823	CbGeAlD
Dabrafenib—Infestation NOS—Topotecan—cervical cancer	0.00141	0.0237	CcSEcCtD
Dabrafenib—Infestation—Topotecan—cervical cancer	0.00141	0.0237	CcSEcCtD
Dabrafenib—Stomatitis—Topotecan—cervical cancer	0.00137	0.0231	CcSEcCtD
Dabrafenib—CYP2C8—renal system—cervical cancer	0.00136	0.00792	CbGeAlD
Dabrafenib—ABCG2—decidua—cervical cancer	0.00135	0.00784	CbGeAlD
Dabrafenib—Epistaxis—Topotecan—cervical cancer	0.00133	0.0223	CcSEcCtD
Dabrafenib—CYP2C8—endometrium—cervical cancer	0.00132	0.00766	CbGeAlD
Dabrafenib—ABCG2—endometrium—cervical cancer	0.00128	0.00744	CbGeAlD
Dabrafenib—Haemoglobin—Topotecan—cervical cancer	0.00127	0.0214	CcSEcCtD
Dabrafenib—Haemorrhage—Topotecan—cervical cancer	0.00126	0.0213	CcSEcCtD
Dabrafenib—ABCG2—mammalian vulva—cervical cancer	0.00124	0.0072	CbGeAlD
Dabrafenib—ABCG2—uterus—cervical cancer	0.00118	0.00686	CbGeAlD
Dabrafenib—Angiopathy—Topotecan—cervical cancer	0.00115	0.0193	CcSEcCtD
Dabrafenib—Immune system disorder—Topotecan—cervical cancer	0.00114	0.0192	CcSEcCtD
Dabrafenib—Mediastinal disorder—Topotecan—cervical cancer	0.00114	0.0192	CcSEcCtD
Dabrafenib—Chills—Topotecan—cervical cancer	0.00113	0.0191	CcSEcCtD
Dabrafenib—Alopecia—Topotecan—cervical cancer	0.00112	0.0188	CcSEcCtD
Dabrafenib—Malnutrition—Topotecan—cervical cancer	0.0011	0.0185	CcSEcCtD
Dabrafenib—CYP2C8—female reproductive system—cervical cancer	0.00109	0.00634	CbGeAlD
Dabrafenib—Back pain—Topotecan—cervical cancer	0.00106	0.0179	CcSEcCtD
Dabrafenib—Muscle spasms—Topotecan—cervical cancer	0.00106	0.0178	CcSEcCtD
Dabrafenib—Anaemia—Topotecan—cervical cancer	0.00102	0.0171	CcSEcCtD
Dabrafenib—CYP2C8—vagina—cervical cancer	0.000988	0.00574	CbGeAlD
Dabrafenib—Leukopenia—Topotecan—cervical cancer	0.000984	0.0166	CcSEcCtD
Dabrafenib—ABCG2—female gonad—cervical cancer	0.000967	0.00561	CbGeAlD
Dabrafenib—ABCG2—vagina—cervical cancer	0.000961	0.00558	CbGeAlD
Dabrafenib—Cough—Topotecan—cervical cancer	0.000959	0.0161	CcSEcCtD
Dabrafenib—Myalgia—Topotecan—cervical cancer	0.000936	0.0158	CcSEcCtD
Dabrafenib—Arthralgia—Topotecan—cervical cancer	0.000936	0.0158	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000929	0.0156	CcSEcCtD
Dabrafenib—CYP3A4—renal system—cervical cancer	0.000924	0.00536	CbGeAlD
Dabrafenib—Infection—Topotecan—cervical cancer	0.000891	0.015	CcSEcCtD
Dabrafenib—Nervous system disorder—Topotecan—cervical cancer	0.00088	0.0148	CcSEcCtD
Dabrafenib—Thrombocytopenia—Topotecan—cervical cancer	0.000878	0.0148	CcSEcCtD
Dabrafenib—Skin disorder—Topotecan—cervical cancer	0.000871	0.0147	CcSEcCtD
Dabrafenib—Hyperhidrosis—Topotecan—cervical cancer	0.000867	0.0146	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000817	0.0138	CcSEcCtD
Dabrafenib—Decreased appetite—Topotecan—cervical cancer	0.00078	0.0131	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000775	0.013	CcSEcCtD
Dabrafenib—Fatigue—Topotecan—cervical cancer	0.000774	0.013	CcSEcCtD
Dabrafenib—Constipation—Topotecan—cervical cancer	0.000767	0.0129	CcSEcCtD
Dabrafenib—CYP3A4—female reproductive system—cervical cancer	0.00074	0.0043	CbGeAlD
Dabrafenib—Gastrointestinal pain—Topotecan—cervical cancer	0.000734	0.0123	CcSEcCtD
Dabrafenib—Abdominal pain—Topotecan—cervical cancer	0.000709	0.0119	CcSEcCtD
Dabrafenib—Body temperature increased—Topotecan—cervical cancer	0.000709	0.0119	CcSEcCtD
Dabrafenib—ABCB1—epithelium—cervical cancer	0.000705	0.00409	CbGeAlD
Dabrafenib—ABCB1—uterine cervix—cervical cancer	0.000699	0.00406	CbGeAlD
Dabrafenib—ABCB1—decidua—cervical cancer	0.000666	0.00387	CbGeAlD
Dabrafenib—Hypersensitivity—Topotecan—cervical cancer	0.000661	0.0111	CcSEcCtD
Dabrafenib—ABCB1—renal system—cervical cancer	0.000654	0.0038	CbGeAlD
Dabrafenib—Asthenia—Topotecan—cervical cancer	0.000644	0.0108	CcSEcCtD
Dabrafenib—Pruritus—Topotecan—cervical cancer	0.000635	0.0107	CcSEcCtD
Dabrafenib—ABCB1—endometrium—cervical cancer	0.000632	0.00367	CbGeAlD
Dabrafenib—ABCG2—lymph node—cervical cancer	0.000621	0.00361	CbGeAlD
Dabrafenib—Diarrhoea—Topotecan—cervical cancer	0.000614	0.0103	CcSEcCtD
Dabrafenib—ABCB1—mammalian vulva—cervical cancer	0.000612	0.00355	CbGeAlD
Dabrafenib—Dizziness—Topotecan—cervical cancer	0.000593	0.00999	CcSEcCtD
Dabrafenib—ABCB1—uterus—cervical cancer	0.000583	0.00338	CbGeAlD
Dabrafenib—Vomiting—Topotecan—cervical cancer	0.00057	0.0096	CcSEcCtD
Dabrafenib—Rash—Topotecan—cervical cancer	0.000566	0.00952	CcSEcCtD
Dabrafenib—Dermatitis—Topotecan—cervical cancer	0.000565	0.00951	CcSEcCtD
Dabrafenib—Headache—Topotecan—cervical cancer	0.000562	0.00946	CcSEcCtD
Dabrafenib—Nausea—Topotecan—cervical cancer	0.000533	0.00897	CcSEcCtD
Dabrafenib—ABCB1—female reproductive system—cervical cancer	0.000524	0.00304	CbGeAlD
Dabrafenib—ABCB1—female gonad—cervical cancer	0.000477	0.00277	CbGeAlD
Dabrafenib—ABCB1—vagina—cervical cancer	0.000474	0.00275	CbGeAlD
Dabrafenib—ABCB1—lymph node—cervical cancer	0.000306	0.00178	CbGeAlD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000215	0.00185	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—EGFR—cervical cancer	0.000214	0.00185	CbGpPWpGaD
Dabrafenib—BRAF—ErbB1 downstream signaling—EGFR—cervical cancer	0.000213	0.00184	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—STAT3—cervical cancer	0.000213	0.00183	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—FGFR3—cervical cancer	0.000212	0.00183	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGFR3—cervical cancer	0.000211	0.00182	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—MTOR—cervical cancer	0.00021	0.00181	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—MTOR—cervical cancer	0.00021	0.00181	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR3—cervical cancer	0.00021	0.00181	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGFR3—cervical cancer	0.000209	0.0018	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000209	0.0018	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—CTNNB1—cervical cancer	0.000207	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—MTOR—cervical cancer	0.000207	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—UBE3A—cervical cancer	0.000206	0.00178	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.000204	0.00176	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000201	0.00174	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—MTOR—cervical cancer	0.0002	0.00173	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.0002	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR3—cervical cancer	0.000197	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	0.000197	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR3—cervical cancer	0.000197	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—MTOR—cervical cancer	0.000195	0.00169	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—FGFR3—cervical cancer	0.000195	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.000194	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—MTOR—cervical cancer	0.000194	0.00167	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR3—cervical cancer	0.000194	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—cervical cancer	0.000193	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR3—cervical cancer	0.000192	0.00166	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—CASP3—cervical cancer	0.000192	0.00165	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CASP8—cervical cancer	0.000189	0.00163	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.000183	0.00158	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.000182	0.00157	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—cervical cancer	0.00018	0.00155	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000179	0.00155	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—cervical cancer	0.000178	0.00154	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TAAR6—cervical cancer	0.000178	0.00154	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000177	0.00153	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—CASP8—cervical cancer	0.000175	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000174	0.0015	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—EGFR—cervical cancer	0.000173	0.00149	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—CTNNB1—cervical cancer	0.000173	0.00149	CbGpPWpGaD
Dabrafenib—BRAF—Disease—WNT2—cervical cancer	0.000169	0.00146	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-DQB1—cervical cancer	0.000168	0.00145	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—CTNNB1—cervical cancer	0.000168	0.00145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MTOR—cervical cancer	0.000166	0.00143	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000166	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—MTOR—cervical cancer	0.000163	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—STAT3—cervical cancer	0.000162	0.0014	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000161	0.00139	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000159	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—MTOR—cervical cancer	0.000159	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—STAT3—cervical cancer	0.000159	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000158	0.00137	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD8A—cervical cancer	0.000157	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—MTOR—cervical cancer	0.000156	0.00135	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—CTNNB1—cervical cancer	0.000156	0.00135	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MTOR—cervical cancer	0.000155	0.00134	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—cervical cancer	0.000155	0.00134	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—STAT3—cervical cancer	0.000155	0.00133	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TAAR6—cervical cancer	0.000152	0.00131	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CASP8—cervical cancer	0.000151	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.000151	0.0013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—EGFR—cervical cancer	0.000151	0.0013	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000151	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—CASP3—cervical cancer	0.00015	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—MTOR—cervical cancer	0.00015	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—MTOR—cervical cancer	0.000149	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000149	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—MTOR—cervical cancer	0.000149	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—MTOR—cervical cancer	0.000148	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—EGFR—cervical cancer	0.000148	0.00127	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—MTOR—cervical cancer	0.000147	0.00127	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—EGFR—cervical cancer	0.000146	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—CTNNB1—cervical cancer	0.000145	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000144	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.000141	0.00122	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—EGFR—cervical cancer	0.00014	0.00121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—WNT2—cervical cancer	0.000139	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—MTOR—cervical cancer	0.000138	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—MTOR—cervical cancer	0.000138	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.000138	0.00119	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CTNNB1—cervical cancer	0.000138	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—MTOR—cervical cancer	0.000137	0.00118	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000137	0.00118	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—MTOR—cervical cancer	0.000136	0.00118	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—STAT3—cervical cancer	0.000136	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.000136	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—MTOR—cervical cancer	0.000135	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGFR3—cervical cancer	0.000134	0.00116	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000134	0.00116	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—EGFR—cervical cancer	0.000133	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—CASP3—cervical cancer	0.000133	0.00114	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CA9—cervical cancer	0.00013	0.00112	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGFR3—cervical cancer	0.000129	0.00111	CbGpPWpGaD
Dabrafenib—BRAF—Disease—WNT5A—cervical cancer	0.000128	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—STAT3—cervical cancer	0.000128	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—STAT3—cervical cancer	0.000126	0.00109	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—CASP3—cervical cancer	0.000125	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—UBE3A—cervical cancer	0.000125	0.00108	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000124	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000124	0.00107	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EGFR—cervical cancer	0.000124	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000123	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—cervical cancer	0.000123	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000123	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKAP13—cervical cancer	0.000122	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.00012	0.00103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—WNT2—cervical cancer	0.000119	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—WNT2—cervical cancer	0.000117	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—EGFR—cervical cancer	0.000117	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—CTNNB1—cervical cancer	0.000116	0.001	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000115	0.000996	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—STAT3—cervical cancer	0.000115	0.000995	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000115	0.00099	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000114	0.000987	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000112	0.000962	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.000112	0.000962	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CASP8—cervical cancer	0.00011	0.000949	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—EGFR—cervical cancer	0.00011	0.000947	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EGFR—cervical cancer	0.000109	0.000942	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HES1—cervical cancer	0.000108	0.000929	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—STAT3—cervical cancer	0.000107	0.000923	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—STAT3—cervical cancer	0.000105	0.000909	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—WNT5A—cervical cancer	0.000105	0.000908	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAAR6—cervical cancer	0.000105	0.000907	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—EGFR—cervical cancer	0.000105	0.000905	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—STAT3—cervical cancer	0.000105	0.000902	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000104	0.0009	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—EGFR—cervical cancer	0.000104	0.0009	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKAP13—cervical cancer	0.000104	0.000899	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—EGFR—cervical cancer	0.000104	0.000896	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—EGFR—cervical cancer	0.000103	0.000891	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—cervical cancer	0.000103	0.00089	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—cervical cancer	0.000101	0.000874	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—cervical cancer	9.72e-05	0.000839	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—cervical cancer	9.72e-05	0.000839	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	9.72e-05	0.000839	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—cervical cancer	9.63e-05	0.000831	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DQB1—cervical cancer	9.61e-05	0.000829	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—cervical cancer	9.57e-05	0.000826	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—cervical cancer	9.55e-05	0.000824	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—cervical cancer	9.5e-05	0.00082	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	9.47e-05	0.000817	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MTOR—cervical cancer	9.42e-05	0.000813	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—cervical cancer	9.18e-05	0.000792	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	9.14e-05	0.000789	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MTOR—cervical cancer	9.05e-05	0.000781	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—cervical cancer	9.03e-05	0.00078	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—WNT5A—cervical cancer	8.99e-05	0.000776	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—cervical cancer	8.97e-05	0.000774	CbGpPWpGaD
Dabrafenib—RAF1—Disease—WNT5A—cervical cancer	8.88e-05	0.000766	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CA9—cervical cancer	8.73e-05	0.000753	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CASP3—cervical cancer	8.67e-05	0.000748	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	8.61e-05	0.000743	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—cervical cancer	8.51e-05	0.000734	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	8.32e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—WNT2—cervical cancer	8.2e-05	0.000708	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NOTCH1—cervical cancer	8.12e-05	0.000701	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CA9—cervical cancer	8.08e-05	0.000698	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CTNNB1—cervical cancer	8.02e-05	0.000693	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	7.68e-05	0.000663	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR3—cervical cancer	7.64e-05	0.000659	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DPB1—cervical cancer	7.46e-05	0.000644	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	7.46e-05	0.000644	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—STAT3—cervical cancer	7.41e-05	0.000639	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HES1—cervical cancer	7.39e-05	0.000637	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR3—cervical cancer	7.34e-05	0.000633	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—STAT3—cervical cancer	7.28e-05	0.000629	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKAP13—cervical cancer	7.2e-05	0.000622	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STAT3—cervical cancer	6.99e-05	0.000604	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—cervical cancer	6.62e-05	0.000571	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CASP8—cervical cancer	6.53e-05	0.000564	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—cervical cancer	6.49e-05	0.00056	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TERT—cervical cancer	6.47e-05	0.000559	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—cervical cancer	6.36e-05	0.000549	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH2—cervical cancer	6.31e-05	0.000544	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—WNT5A—cervical cancer	6.22e-05	0.000537	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—cervical cancer	5.99e-05	0.000517	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR3—cervical cancer	5.94e-05	0.000513	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—cervical cancer	5.83e-05	0.000503	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	5.65e-05	0.000487	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOTCH1—cervical cancer	5.58e-05	0.000481	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	5.44e-05	0.00047	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—cervical cancer	5.44e-05	0.00047	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—cervical cancer	5.4e-05	0.000466	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MTOR—cervical cancer	5.38e-05	0.000464	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—cervical cancer	5.37e-05	0.000463	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—cervical cancer	5.27e-05	0.000455	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HES1—cervical cancer	5.17e-05	0.000446	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—MTOR—cervical cancer	5.16e-05	0.000445	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—cervical cancer	5.15e-05	0.000445	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HES1—cervical cancer	5.11e-05	0.000441	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA9—cervical cancer	5.02e-05	0.000433	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—cervical cancer	4.77e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—STAT3—cervical cancer	4.7e-05	0.000406	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TERT—cervical cancer	4.53e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—cervical cancer	4.49e-05	0.000387	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TERT—cervical cancer	4.48e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—cervical cancer	4.45e-05	0.000384	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA9—cervical cancer	4.37e-05	0.000377	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH2—cervical cancer	4.36e-05	0.000377	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	4.31e-05	0.000372	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—cervical cancer	4.28e-05	0.000369	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTOR—cervical cancer	4.18e-05	0.000361	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—cervical cancer	4.17e-05	0.00036	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—cervical cancer	4.16e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—cervical cancer	4.11e-05	0.000355	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH1—cervical cancer	3.9e-05	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOTCH1—cervical cancer	3.86e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP8—cervical cancer	3.81e-05	0.000328	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—cervical cancer	3.78e-05	0.000326	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—cervical cancer	3.7e-05	0.00032	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—cervical cancer	3.63e-05	0.000313	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	3.62e-05	0.000312	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES1—cervical cancer	3.58e-05	0.000309	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—cervical cancer	3.54e-05	0.000306	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—cervical cancer	3.52e-05	0.000304	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—cervical cancer	3.28e-05	0.000283	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—cervical cancer	3.23e-05	0.000279	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—cervical cancer	3.14e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MTOR—cervical cancer	3.13e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—cervical cancer	3.13e-05	0.00027	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—cervical cancer	2.93e-05	0.000253	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—cervical cancer	2.93e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—cervical cancer	2.89e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—cervical cancer	2.89e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—cervical cancer	2.88e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—cervical cancer	2.78e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—cervical cancer	2.7e-05	0.000233	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA9—cervical cancer	2.69e-05	0.000232	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—cervical cancer	2.69e-05	0.000232	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—cervical cancer	2.59e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—cervical cancer	2.56e-05	0.000221	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—cervical cancer	2.42e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—cervical cancer	2.41e-05	0.000208	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—cervical cancer	2.26e-05	0.000195	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—cervical cancer	2.23e-05	0.000193	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—cervical cancer	2.2e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—cervical cancer	2.06e-05	0.000177	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—cervical cancer	2.04e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—cervical cancer	2.03e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—cervical cancer	2.02e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—cervical cancer	1.86e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—cervical cancer	1.79e-05	0.000155	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—cervical cancer	1.77e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—cervical cancer	1.73e-05	0.000149	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—cervical cancer	1.56e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—cervical cancer	1.42e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—cervical cancer	1.19e-05	0.000103	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—cervical cancer	1.09e-05	9.43e-05	CbGpPWpGaD
